G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
01 Julio 2024 - 7:00AM
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology
company, today announced that the Company has been added to the
broad-market Russell 3000® and
small-cap Russell 2000® Indexes as of the conclusion
of the 2024 Russell US Indexes annual reconstitution, effective at
the open of US equity markets today, Monday, July 1, 2024.
The annual Russell US Indexes reconstitution captures the 4,000
largest US stocks as of Tuesday, April 30th, ranking them by total
market capitalization. Membership in the US all-cap Russell 3000
Index, which remains in place for one year, means automatic
inclusion in the large-cap Russell 1000 Index or small-cap Russell
2000 Index as well as the appropriate growth and value style
indexes. FTSE Russell determines membership for its Russell indexes
primarily by objective, market-capitalization rankings, and style
attributes.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. According to the data as of the end
of December 2023, about $10.5 trillion in assets are benchmarked
against the Russell US indexes, which belong to FTSE Russell, a
prominent global index provider.
For more information on the Russell 3000® Index and the Russell
indexes reconstitution, go to the “Russell Reconstitution” section
on the FTSE Russell website.
About FTSE RussellFTSE Russell is a leading
global provider of benchmarking, analytics, and data solutions for
investors, giving them a precise view of the market relevant to
their investment process. A comprehensive range of reliable and
accurate indexes provides investors worldwide with the tools they
require to measure and benchmark markets across asset classes,
styles, or strategies.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. For over 30 years,
leading asset owners, asset managers, ETF providers and investment
banks have chosen FTSE Russell indexes to benchmark their
investment performance and create ETFs, structured products, and
index-based derivatives.
FTSE Russell is focused on applying the highest industry
standards in index design and governance, employing transparent
rules-based methodology informed by independent committees of
leading market participants. FTSE Russell fully embraces the IOSCO
Principles, and its Statement of Compliance has received
independent assurance. Index innovation is driven by client needs
and customer partnerships, allowing FTSE Russell to continually
enhance the breadth, depth and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit
https://www.lseg.com/en/ftse-russell
About G1 TherapeuticsG1 Therapeutics, Inc. is a
commercial-stage oncology biopharmaceutical company whose mission
is to develop and deliver next-generation therapies that improve
the lives of those affected by cancer, including the Company’s
first commercial product, COSELA® (trilaciclib). G1’s goal is to
provide innovative therapeutic advances for people living with
cancer. G1 is based in Research Triangle Park, N.C. For additional
information, please visit http://www.g1therapeutics.com and follow
us on X (formerly known as Twitter) @G1Therapeutics and
LinkedIn.
G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and
the COSELA logo are trademarks of G1 Therapeutics, Inc.
Contact:
Will RobertsCommunications OfficerVice President, Investor
Relations and Corporate Communications(919) 907-1944
wroberts@g1therapeutics.com
G1 Therapeutics (NASDAQ:GTHX)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
G1 Therapeutics (NASDAQ:GTHX)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024